Accéder au contenu
Merck

CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models.

Scientific reports (2020-03-27)
Anurag Rathore, Sho Iketani, Pengfei Wang, Manxue Jia, Vincent Sahi, David D Ho
RÉSUMÉ

The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a genome-wide functional knockout screen using CRISPR-Cas9 in a HIV-1 latency cell line model. This screen identified IWS1, POLE3, POLR1B, PSMD1, and TGM2 as potential regulators of HIV-1 latency, of which PSMD1 and TMG2 could be confirmed pharmacologically. Further investigation of PSMD1 revealed that an interacting enzyme, the deubiquitinase UCH37, was also involved in HIV-1 latency. We therefore conducted a comprehensive evaluation of the deubiquitinase family by gene knockout, identifying several deubiquitinases, UCH37, USP14, OTULIN, and USP5 as possible HIV-1 latency regulators. A specific inhibitor of USP14, IU1, reversed HIV-1 latency and displayed synergistic effects with other latency reversal agents. IU1 caused degradation of TDP-43, a negative regulator of HIV-1 transcription. Collectively, this study is the first comprehensive evaluation of deubiquitinases in HIV-1 latency and establishes that they may hold a critical role.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Sigma-Aldrich
SAHA, ≥98% (HPLC)
Sigma-Aldrich
(+)-JQ1, ≥98% (HPLC)
Sigma-Aldrich
Romidepsin, ≥98% (HPLC)
Sigma-Aldrich
IU1, ≥98% (HPLC)
Sigma-Aldrich
Prostratin, ≥98% (HPLC)
Sigma-Aldrich
Transglutaminase 2 Inhibitor, ZDON, A cell-permeable, peptide-based, irreversible inhibitor of transglutaminase 2 (TG2; IC₅₀ = 150 nM for recombinant TG2). Reacts with the active site cysteine of TG2.
Sigma-Aldrich
Tubacin, ≥98% (HPLC)
Sigma-Aldrich
Acitretin, ≥98.0% (HPLC)
Sigma-Aldrich
Ingenol-3-angelate, ≥95% (HPLC)
Sigma-Aldrich
TCID, ≥98% (HPLC)